Compare Genworth Financial Inc Common Stock (GNW) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genworth Financial Inc Common Stock vs McKesson Corporation — how do they compare? Genworth Financial Inc Common Stock trades at $8.94 (market cap $3.33B), while McKesson Corporation trades at $992.58 (market cap $113.86B). The key difference: McKesson Corporation is far larger — about 34.2× Genworth Financial Inc Common Stock's market cap, and McKesson Corporation pays a 0.39% dividend while Genworth Financial Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genworth Financial Inc Common Stock for 0 Days and McKesson Corporation for 74 Days on average.
| GNW | MCK | |
|---|---|---|
Market Cap | $3.33B | $113.86B |
Volume | 3,324,561 | 767,917 |
Sector | Financials | Health |
52-Week High | $10.60 | $995.69 |
52-Week Low | $7.94 | $725.17 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $2.85B | $120.40B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
MCK trades at $961.88, up 0.64% today, showing strong momentum with three consecutive earnings beats and a bullish technical outlook. The stock benefits from robust revenue growth reaching $359.1B in 2025 and positive sentiment from the recent CVS Health partnership extension through 2032. Analyst consensus remains strongly bullish with 81% buy ratings and a $956.43 price target, though the current price slightly exceeds this target.
MCK presents a compelling investment case with solid fundamentals and growth trajectory, though investors should monitor margin pressures and competitive dynamics. The company's strong cash flow generation and institutional support provide stability, while technical indicators suggest near-term resistance around $967-$978 levels could limit immediate upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Genworth Financial Inc Common Stock
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
